Effectiveness of AromatherapyNCT06400979

Aromatherapy for Management of Pain, Anxiety, and Nausea in the Acute Care Setting

A study testing Elequil aromatab in people with Effectiveness of Aromatherapy, run by University of California, Davis at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for: Effectiveness of Aromatherapy
What is being tested?: Elequil aromatab
Type of treatment: Medical device
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 94 participants
Where: 1 siteUnited States
Study dates: 1 Dec 2020to 1 May 2022
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Age 18 years or older,
Admission to Tower 4 for an anticipated inpatient stay >24 hours,
Alert and oriented,
Capable of using a visual scale to self-report symptoms,
Naïve to the use of aromatherapy for the use of decreasing pain, anxiety and/or nausea to participate,
Not on a pediatric service.

Who cannot join

Cognitively impaired,
Post-op from an otolaryngologic surgery (another study was being conducted concurrently with this patient population and we did not want to interfere with those results),
Known impaired olfactory function (limited or no sense of smell),
On any psychiatric holds (e.g., 5150's),
Known allergies to essential oils,
Sensitive or allergic to plants (specifically to lavender plants, orange blossoms, sandalwood trees, or peppermint leaves) as essential oils are natural aromas derived from plants,

Show all 12Show fewer

Active participant of another Research Protocol,
Admitted as a "short stay" or on "observation" status,
Have a known history of Atrial Fibrillation. The use of peppermint has known effects on stimulating atrial fibrillation,
Is a prisoner,
Known pregnancy, or
Expected to be transferred out of Tower 4 and/or discharged from the hospital within twenty-four hours.

Trial locations and contacts

1 site in 1 country.

United States1 site

UC Davis Medical Center
Sacramento, California, 95817

Other trials in United States

About this study

The purpose of this interventional study is to investigate the effects of aromatherapy on an acute care unit and whether it is effective in decreasing physical or emotional stressors that occur as a hospitalized patient. This study aimed to expand the limited literature on aromatherapy use in hospitalized adults and its effectiveness in decreasing pain, anxiety, and nausea. The hypothesis was that use of aromatherapy would decrease pain, anxiety and nausea in hospitalized adults and increase patient satisfaction. While there is anecdotal evidence of its efficacy, few studies exist evaluating its effectiveness within peer-reviewed journals, specifically on acute care medical surgical units.

Read the detailed description

The goal for the study was to collect a sample of one hundred adult patients admitted to an acute care medical surgical unit. A quasi-experimental study with a single-arm pre-/post-test design evaluated one-time use of inhaled aromatherapy on hospitalized adults on an acute care unit. Pre-test tools included a numeric pain rating scale, facial anxiety scale and Halpin's 0-5 nausea scale. Aromatherapy (Elequil aromatabs) was administered for 8 hours. Sleep, satisfaction, well-being, and concurrent medication use were assessed post-aromatherapy. Descriptive and inferential statistics were performed. These subjects had to be conscious, oriented, able to consent, and able to understand the purpose of the study. Exclusion criteria were otolaryngology free flap patients (as this was a study being conducted on an otolaryngology acute care unit and another study was occurring with this population), patients with known allergies to essential oils, those taking sleep medications, or who have an aroma/essential oil contraindication. The use of a pre and post survey was used to measure the effectiveness of aromatherapy on pain, anxiety, and nausea. A baseline assessment was made of these ailments via Qualtrix. Subjects chose the aromatherapy tab fragrance that best fit their chief complaint, which was placed on their gown. After eight hours, a post-application survey to assess pain, anxiety, nausea, sleep/relaxation, overall satisfaction, and overall wellbeing was administered via Qualtrix. A numeric pain scale from 0-10, a 0-5 Likert Anxiety scale and a 0-5 nausea scale were used to measure efficacy. Sleep, satisfaction, and wellbeing was assessed with yes/no. A chart review to determine any measurable benefits in the reduction of related medications while using aromatherapy was to be conducted once one hundred subjects were obtained. The period for this study was approximately fifteen months.

Conditions: Effectiveness of Aromatherapy
Being tested: Elequil aromatab
Keywords: aromatherapy, acute care unit, medical surgical unit, inhaled aromatherapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Elequil aromatabDevice
Aromatherapy impregnated tab utilized to dispense inhaled scent for the study

Study groups in NCT06400979
Study group	Role	What they receive
Aromatherapy aromatab	Experimental	Interventional aromatherapy tab used to deliver inhaled aromatherapy to participants Receives: Device: Elequil aromatab

What is being measured

The primary outcome is the main question the study is designed to answer.

Numerical Rating Pain Scale
The Numerical Rating Pain Scale measures pain experienced right now based on a 11-point Likert scale with choices of 0 = no pain, 5 = Moderate pain, 10 = Worst possible pain.
Measured: Pre-Post Aromatherapy Administration (8 hours)
Nausea Scale
Nausea Scale: 0-5 Nausea Scale. 0 - No nausea and 5 - severe nausea
Measured: Pre-Post Aromatherapy Administration (8 hours)
Anxiety Likert Scale
This one-item scale consisted of five evenly spaced numbers each anchored to a level of anxiety (0 = not at all anxious, 2 = a little anxious, 3 = moderately anxious, 4 = very anxious, 5 = extremely anxious).
Measured: Pre-Post Aromatherapy Admin (8 hours)

Secondary outcomes (3)

Patient Satisfaction
The use of a post-survey to evaluate effectiveness of aromatherapy on patient satisfaction using a yes or no response.
Measured: 8 hours
Well-being
The use of a post-survey to evaluate effectiveness of aromatherapy on the subject's well-being using a yes or no response.
Measured: 8 hours
Increased Sleep
The use of a post-survey to evaluate effectiveness of aromatherapy in increasing sleep using a yes or no response.
Measured: 8 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Dec 20201 May 2022

First posted6 May 2024
Study start1 Dec 2020
Primary completion1 May 2022
Study completion1 May 2022

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (16)Papers the sponsor has linked to this study.
Other trials for Effectiveness of AromatherapyStudies of the same condition, open and under way.
More trials run by University of California, DavisThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Supportive care
Allocation: Not applicable
Intervention model: Single group
Model description: To collect a sample of one hundred adult patients admitted to an acute care medical surgical unit. A quasi-experimental study with a single-arm pre-/post-test design evaluated one-time use of inhaled aromatherapy on hospitalized adults on an acute care unit. Pre-test tools included a numeric pain rating scale, facial anxiety scale and 0-5 nausea scale by Halpin et al. Aromatherapy (Elequil aromatabs) was administered for 8 hours. Sleep, satisfaction, well-being, and concurrent medication use were assessed post-aromatherapy.
Masking: None (open label)
Enrolment: 94 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06400979
Sponsor's protocol ID: 1636824
Status last verified: May 2026
First submitted: 6 Jan 2024
Last updated: 8 Jun 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: Yes
Individual data sharing: No: We will not be sharing subject data after the conclusion of the study

Publications

Frosch PJ, Johansen JD, Menne T, Pirker C, Rastogi SC, Andersen KE, Bruze M, Goossens A, Lepoittevin JP, White IR. Further important sensitizers in patients sensitive to fragrances. Contact Dermatitis. 2002 Nov;47(5):279-87. doi: 10.1034/j.1600-0536.2002.470204.x.
PubMed 12534532
Bingham LJ, Tam MM, Palmer AM, Cahill JL, Nixon RL. Contact allergy and allergic contact dermatitis caused by lavender: A retrospective study from an Australian clinic. Contact Dermatitis. 2019 Jul;81(1):37-42. doi: 10.1111/cod.13247. Epub 2019 Apr 16.
PubMed 30779160
Boehm K, Bussing A, Ostermann T. Aromatherapy as an adjuvant treatment in cancer care--a descriptive systematic review. Afr J Tradit Complement Altern Med. 2012 Jul 1;9(4):503-18. doi: 10.4314/ajtcam.v9i4.7. eCollection 2012.
PubMed 23983386
Buckle J. The role of aromatherapy in nursing care. Nurs Clin North Am. 2001 Mar;36(1):57-72.
PubMed 11342402
Johnson JR, Rivard RL, Griffin KH, Kolste AK, Joswiak D, Kinney ME, Dusek JA. The effectiveness of nurse-delivered aromatherapy in an acute care setting. Complement Ther Med. 2016 Apr;25:164-9. doi: 10.1016/j.ctim.2016.03.006. Epub 2016 Mar 7.
PubMed 27062964
Cho MY, Min ES, Hur MH, Lee MS. Effects of aromatherapy on the anxiety, vital signs, and sleep quality of percutaneous coronary intervention patients in intensive care units. Evid Based Complement Alternat Med. 2013;2013:381381. doi: 10.1155/2013/381381. Epub 2013 Feb 17.
PubMed 23476690
Cooke B, Ernst E. Aromatherapy: a systematic review. Br J Gen Pract. 2000 Jun;50(455):493-6.
PubMed 10962794
Halpin A, Huckabay LM, Kozuki JL, Forsythe D. Weigh the benefits of using a 0-to-5 nausea scale. Nursing. 2010 Nov;40(11):18-20. doi: 10.1097/01.NURSE.0000389030.33760.7a. No abstract available.
PubMed 20975423
Lakhan SE, Sheafer H, Tepper D. The Effectiveness of Aromatherapy in Reducing Pain: A Systematic Review and Meta-Analysis. Pain Res Treat. 2016;2016:8158693. doi: 10.1155/2016/8158693. Epub 2016 Dec 14.
PubMed 28070420
Lis-Balchin M. Essential oils and 'aromatherapy': their modern role in healing. J R Soc Health. 1997 Oct;117(5):324-9. doi: 10.1177/146642409711700511.
PubMed 9519666
Long L, Huntley A, Ernst E. Which complementary and alternative therapies benefit which conditions? A survey of the opinions of 223 professional organizations. Complement Ther Med. 2001 Sep;9(3):178-85. doi: 10.1054/ctim.2001.0453.
PubMed 11926432
Maddocks-Jennings W, Wilkinson JM. Aromatherapy practice in nursing: literature review. J Adv Nurs. 2004 Oct;48(1):93-103. doi: 10.1111/j.1365-2648.2004.03172.x.
PubMed 15347415
Moeini M, Khadibi M, Bekhradi R, Mahmoudian SA, Nazari F. Effect of aromatherapy on the quality of sleep in ischemic heart disease patients hospitalized in intensive care units of heart hospitals of the Isfahan University of Medical Sciences. Iran J Nurs Midwifery Res. 2010 Fall;15(4):234-9.
PubMed 22049287
Quinlan-Colwell AD. Understanding the paradox of patient pain and patient satisfaction. J Holist Nurs. 2009 Sep;27(3):177-82; quiz 183-5. doi: 10.1177/0898010109332758. Epub 2009 Jul 8.
PubMed 19587387
Shin BC, Lee MS. Effects of aromatherapy acupressure on hemiplegic shoulder pain and motor power in stroke patients: a pilot study. J Altern Complement Med. 2007 Mar;13(2):247-51. doi: 10.1089/acm.2006.6189.
PubMed 17388768

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement:
Aromatherapy
Not yet recruiting
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
Multiple Sclerosis (MS), Neurogenic Bladder Disorder
Recruiting
Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy.
Breast Cancer
Recruiting
Effectiveness of Aromatherapy and Digital Anesthesia in Managing Dental Anxiety and Pain in Children
Pain, Dental Anxiety
Recruiting
Aromatherapy in Reducing PONV for Total Joint Replacement Patients
Total Joint Replacement Surgery, Postoperative Nausea and Vomiting

All Effectiveness of Aromatherapy trials

Study at a glance

From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Aromatherapy for Management of Pain, Anxiety, and Nausea in the Acute Care Setting
ClinicalTrials.gov ID: NCT06400979
Acronym / sponsor ID: 1636824
Conditions: Effectiveness of Aromatherapy
Keywords: aromatherapy, acute care unit, medical surgical unit, inhaled aromatherapy
Study type: Interventional
Recruitment status: Completed
Enrolment: 94 participants (actual)
Lead sponsor: University of California, DavisUniversity, hospital or other
Collaborators: Beekley Medical
Study start: 1 Dec 2020 (actual)
Primary completion: 1 May 2022 (actual)
Study completion: 1 May 2022 (actual)
First posted: 6 May 2024 (actual)
Results: Posted 18 Apr 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Supportive care
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1
Model description: To collect a sample of one hundred adult patients admitted to an acute care medical surgical unit. A quasi-experimental study with a single-arm pre-/post-test design evaluated one-time use of inhaled aromatherapy on hospitalized adults on an acute care unit. Pre-test tools included a numeric pain rating scale, facial anxiety scale and 0-5 nausea scale by Halpin et al. Aromatherapy (Elequil aromatabs) was administered for 8 hours. Sleep, satisfaction, well-being, and concurrent medication use were assessed post-aromatherapy.

Arm	Type	Receives
Aromatherapy aromatab	Experimental	Device: Elequil aromatabInterventional aromatherapy tab used to deliver inhaled aromatherapy to participants

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (6 listed)

Age 18 years or older,
Admission to Tower 4 for an anticipated inpatient stay >24 hours,
Alert and oriented,
Capable of using a visual scale to self-report symptoms,
Naïve to the use of aromatherapy for the use of decreasing pain, anxiety and/or nausea to participate,

Key exclusion criteria (12 listed)

Cognitively impaired,
Post-op from an otolaryngologic surgery (another study was being conducted concurrently with this patient population and we did not want to interfere with those results),
Known impaired olfactory function (limited or no sense of smell),
On any psychiatric holds (e.g., 5150's),
Known allergies to essential oils,

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Elequil aromatabAromatherapy impregnated tab utilized to dispense inhaled scent for the study	Device	Aromatherapy aromatab

Primary outcome

Numerical Rating Pain Scale
Time frame: Pre-Post Aromatherapy Administration (8 hours)
The Numerical Rating Pain Scale measures pain experienced right now based on a 11-point Likert scale with choices of 0 = no pain, 5 = Moderate pain, 10 = Worst possible pain.
Nausea Scale
Time frame: Pre-Post Aromatherapy Administration (8 hours)
Nausea Scale: 0-5 Nausea Scale. 0 - No nausea and 5 - severe nausea
Anxiety Likert Scale
Time frame: Pre-Post Aromatherapy Admin (8 hours)
This one-item scale consisted of five evenly spaced numbers each anchored to a level of anxiety (0 = not at all anxious, 2 = a little anxious, 3 = moderately anxious, 4 = very anxious, 5 = extremely anxious).

3 secondary outcomes

Patient Satisfaction
Time frame: 8 hours
Well-being
Time frame: 8 hours
Increased Sleep
Time frame: 8 hours

Results and safety

Results posted to the registry on 18 Apr 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Aromatherapy Aromatab	94	64

Primary outcome: Numerical Rating Pain Scale

Time frame: Pre-Post Aromatherapy Administration (8 hours). Mean (Standard Deviation). Unit: score on a scale

Measure	Aromatherapy Aromatab n = 94
Pre-score for subjects utilizing Aromatherapy for pain	5.7 (3.0)
Post-score for subjects utilizing Aromatherapy for symptom management for pain	5.3 (2.9)
Pain: Post vs Pre	-1 (2.9)

Aromatherapy Aromatab: p = 0.008, ANCOVA

Population analysed: Number of subjects utilizing aromatherapy tabs to decrease pain

Primary outcome: Nausea Scale

Time frame: Pre-Post Aromatherapy Administration (8 hours). Mean (Standard Deviation). Unit: score on a scale

Measure	Aromatherapy Aromatab n = 94
Pre-score for subjects utilizing aromatherapy to decrease nausea	1.5 (1.7)
Post-score for subjects utilizing aromatherapy for symptom management for nausea	1.2 (1.6)

Aromatherapy Aromatab: p = 0.13, ANCOVA

Population analysed: Total number of subjects participating in the study

Primary outcome: Anxiety Likert Scale

Time frame: Pre-Post Aromatherapy Admin (8 hours). Mean (Standard Deviation). Unit: score on a scale

Measure	Aromatherapy Aromatab n = 94
Pre-score for subjects utilizing aromatherapy to decrease anxiety	2.6 (1.9)
Post-score for subjects utilizing aromatherapy for symptom management for anxiety	1.8 (1.6)

Aromatherapy Aromatab: p <0.0001, ANCOVA

Population analysed: Number of subjects utilizing aromatherapy to decrease anxiety.

3 secondary outcomes are reported in the full results.

Adverse events

Time frame: Adverse event data was collected for the duration of patient enrollment in the study (8 hours during hospitalization).. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Aromatherapy Aromatab Used to Measure Effectiveness on Decreasing Pain	0 of 94 (0%)	0 of 94 (0%)	0 of 94

Limitations and caveats (from the sponsor): Limitations included slow enrollment, study design and missing post-test scores. We had a slow start with enrolling subjects as many patients either did not fit the eligibility criteria, or they were not interested. In addition, with the COVID pandemic, it made it even more difficult to enroll patients. Finding our requisite number of subjects was more challenging than expected.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Results publication: PubMed 12534532Frosch PJ, Johansen JD, Menne T, Pirker C, Rastogi SC, Andersen KE, Bruze M, Goossens A, Lepoittevin JP, White IR. Further important sensitizers in patients sensitive to fragrances. Contact Dermatitis. 2002 Nov;47(5):279-87. doi: 10.1034/j.1600-0536.2002.470204.x.
Results publication: PubMed 30779160Bingham LJ, Tam MM, Palmer AM, Cahill JL, Nixon RL. Contact allergy and allergic contact dermatitis caused by lavender: A retrospective study from an Australian clinic. Contact Dermatitis. 2019 Jul;81(1):37-42. doi: 10.1111/cod.13247. Epub 2019 Apr 16.
Results publication: PubMed 23983386Boehm K, Bussing A, Ostermann T. Aromatherapy as an adjuvant treatment in cancer care--a descriptive systematic review. Afr J Tradit Complement Altern Med. 2012 Jul 1;9(4):503-18. doi: 10.4314/ajtcam.v9i4.7. eCollection 2012.
Results publication: PubMed 11342402Buckle J. The role of aromatherapy in nursing care. Nurs Clin North Am. 2001 Mar;36(1):57-72.
Results publication: PubMed 27062964Johnson JR, Rivard RL, Griffin KH, Kolste AK, Joswiak D, Kinney ME, Dusek JA. The effectiveness of nurse-delivered aromatherapy in an acute care setting. Complement Ther Med. 2016 Apr;25:164-9. doi: 10.1016/j.ctim.2016.03.006. Epub 2016 Mar 7.
Results publication: PubMed 23476690Cho MY, Min ES, Hur MH, Lee MS. Effects of aromatherapy on the anxiety, vital signs, and sleep quality of percutaneous coronary intervention patients in intensive care units. Evid Based Complement Alternat Med. 2013;2013:381381. doi: 10.1155/2013/381381. Epub 2013 Feb 17.
Results publication: PubMed 10962794Cooke B, Ernst E. Aromatherapy: a systematic review. Br J Gen Pract. 2000 Jun;50(455):493-6.
Results publication: PubMed 20975423Halpin A, Huckabay LM, Kozuki JL, Forsythe D. Weigh the benefits of using a 0-to-5 nausea scale. Nursing. 2010 Nov;40(11):18-20. doi: 10.1097/01.NURSE.0000389030.33760.7a. No abstract available.
Results publication: PubMed 28070420Lakhan SE, Sheafer H, Tepper D. The Effectiveness of Aromatherapy in Reducing Pain: A Systematic Review and Meta-Analysis. Pain Res Treat. 2016;2016:8158693. doi: 10.1155/2016/8158693. Epub 2016 Dec 14.
Results publication: PubMed 9519666Lis-Balchin M. Essential oils and 'aromatherapy': their modern role in healing. J R Soc Health. 1997 Oct;117(5):324-9. doi: 10.1177/146642409711700511.
Results publication: PubMed 11926432Long L, Huntley A, Ernst E. Which complementary and alternative therapies benefit which conditions? A survey of the opinions of 223 professional organizations. Complement Ther Med. 2001 Sep;9(3):178-85. doi: 10.1054/ctim.2001.0453.
Results publication: PubMed 15347415Maddocks-Jennings W, Wilkinson JM. Aromatherapy practice in nursing: literature review. J Adv Nurs. 2004 Oct;48(1):93-103. doi: 10.1111/j.1365-2648.2004.03172.x.
Instructional video on how to use aromatabLink provided by the sponsor.
Individual participant dataSharing planned: No. We will not be sharing subject data after the conclusion of the study

Related trials for Effectiveness of Aromatherapy

Recruiting
Inhalation Aromatherapy for Patients Undergoing Conservative Sharp Wound Debridement:
Aromatherapy
Not yet recruiting
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
Multiple Sclerosis (MS), Neurogenic Bladder Disorder
Recruiting
Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy.
Breast Cancer
Recruiting
Effectiveness of Aromatherapy and Digital Anesthesia in Managing Dental Anxiety and Pain in Children
Pain, Dental Anxiety
Recruiting
Aromatherapy in Reducing PONV for Total Joint Replacement Patients
Total Joint Replacement Surgery, Postoperative Nausea and Vomiting

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Elequil aromatab in people with Effectiveness of Aromatherapy, run by University of California, Davis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Numerical Rating Pain Scale (time frame: Pre-Post Aromatherapy Administration (8 hours)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06400979, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.